Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis

Published:2020-10-27 Issue: Volume: Page:1-6
ISSN:0148-0545
Container-title:Drug and Chemical Toxicology
language:en
Short-container-title:Drug and Chemical Toxicology

Author:

Ling Yiwen¹^ORCID,Li Rui²,Zhong Jiankai³,Zhao Ying¹,Chen Zhuowen¹

Affiliation:

1. Department of Hematology, First People’s Hospital of Foshan, Foshan, China

2. Department of Internal Medicine, Foshan Maternal and Child Health Hospital, Foshan, China

3. Department of Cardiology, Shunde Hospital, Southern Medical University, Guangdong, China

Publisher

Informa UK Limited

Subject

Chemical Health and Safety,Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/01480545.2020.1835945

Reference39 articles.

1. In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

2. Meta-analysis in clinical trials

3. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

4. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022;Pharmaceuticals;2024-06-21

2. Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews;Annals of Hematology;2023-11-08

3. Molecular Cardiotoxic Effects of Proteasome Inhibitors Carfilzomib and Ixazomib and Their Combination with Dexamethasone Involve Mitochondrial Dysregulation;Cardiovascular Toxicology;2023-02-21

4. Cardiac Adverse Events Associated with Multiple Myeloma Patients Treated with Proteasome Inhibitors;Oncology;2023

5. Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost;International Journal of Molecular Sciences;2022-11-15